AffordableGLP-1Providers Take the quiz
Home › Journal › News analysis

News analysis · FDA warning letter 737905 · prices read November 20, 2026

Is a $78-a-month compounded GLP-1 legit? What FDA’s RonanRx letter shows

Released: · Last reviewed:

A $78-a-month compounded semaglutide price is not proof of a scam: on November 20, 2026, 12 of the 49 semaglutide programs on our sheet printed a lowest figure of $78 or less. FDA’s October 30 warning letter to RonanRx objected to its claims, not its price.

Takeaway: every sub-$78 figure on our sheet depends on a sale, a prepaid term, a membership or an unprinted plan length; apart from NextMeds’ $49 “starting at” figure, the lowest price on our sheet printed as month to month with none of those is Mondae’s $87.

What did FDA’s letter to RonanRx actually say?

FDA’s warning letter 737905, dated October 30, 2026 and posted November 3, says RonanRx made false or misleading claims about compounded semaglutide and tirzepatide on its website and its X account. It names three problems, and the price is not one of them on its own.

RonanRx had 15 working days to respond. A warning letter is FDA’s notice of alleged violations, not a court finding, a recall or a ban, and no response or close-out letter had been posted when we read the letter on November 20, 2026.

Is $78 a month unusually low for compounded semaglutide?

No. It sits in the cheapest quarter of the programs on our sheet, not off the chart. On November 20, 2026 our sheet held 49 compounded semaglutide programs, each counted once at the lowest all-in monthly figure it prints. Exactly 12 of them, about a quarter, print $78 or less, and the median is $134. The full list, with every condition, is in our price index.

Compounded semaglutide: lowest monthly figure per program, November 20, 2026Bar chart of 49 programs by price band. Under $60: 2 programs; $60 to $79: 11; $80 to $99: 7; $100 to $119: 3; $120 to $139: 4; $140 to $159: 9; $160 to $199: 7; $200 to $299: 6. RonanRx’s advertised $78 falls in the $60 to $79 band; the two lowest bands are shaded amber.Number of programs (lowest all-in figure each prints, USD per month)04812Under $602$60–7911$80–997$100–1193$120–1394$140–1599$160–1997$200–2996Programs per price band
Source: first-party reads of each program’s pricing page on November 20, 2026, except Embody, NewMeMeds and bmiMD (carried from earlier first-party reads) and four rows reported by third parties (TMates, Luvo, Care Bare Rx and Enhance MD), as listed in our semaglutide table. Each program appears once, at its lowest printed figure including any membership; sale and prepaid figures count, first-month-only offers do not.
The chart’s data: compounded semaglutide programs by lowest monthly figure, November 20, 2026 (49 programs)
Price band (USD per month)ProgramsShare of the sheet
Under $6024%
$60–791122%
$80–99714%
$100–11936%
$120–13948%
$140–159918%
$160–199714%
$200–299612%

So a low price alone cannot separate a careful seller from a careless one. What separates them is what the low price depends on, and whether the seller tells you.

What does each sub-$78 price on our sheet depend on?

Every one of the 12 figures at or below $78 carries a condition or leaves something unprinted. Four are sales or promo codes, six need a prepaid or longest plan, one needs a yearly membership, and one, NextMeds, is a “starting at” figure with no printed plan term.

Compounded semaglutide figures at or below $78 a month and the condition behind each (USD; first-party reads, November 20, 2026, unless marked)
ProgramFigureWhat it depends onConditionSource · read
WellMedr$39“Starting at” during a Black Friday sale, shipped every 4 weeks; plan term not printedSalewellmedr.com · 2026-11-20
NextMeds$49“Starting at”, same price every month and dose; plan term not printedNo printed termnextmeds.com · 2026-11-20
Mondae$696-month plan paid up front ($414); $87 month to monthPrepaidmondae.com · 2026-11-20
Yucca Health$6912-month plan paid up front ($828); $89 month to monthPrepaidYucca help center · 2026-11-20
Gala GLP-1$69Annual plan billed once a year; price depends on state and dosePrepaidgalaglp1.com · 2026-11-20
Embody$69Prepaid year of $828, payments finalPrepaidjoinem.co · 2026-10-15 (HTTP 429 on 11-20)
Fridays$69“$69/mo” with a 75%-off promo code; the same page also prints $150 a month and $279 a month on an annual planPromo codejoinfridays.com · 2026-11-20
SnagRx$69Pre-Black Friday sale against a $299 list priceSalesnagrx.com · 2026-11-20
NewMeMeds$7512-month plan; $89 month to month; payment basis not printed12-month plannewmemeds.com · 2026-09-20 (site unreachable 11-20)
PreventiveMD$75“As low as … all-in” on its longest planPrepaidpreventivemd.com · 2026-11-20
Collective$76$59 medication plus a $199 yearly membershipMembershipcollective.org · 2026-11-20
Sunlight$78Flat monthly rate under an “Early Black Friday” bannerSalesunlight.com · 2026-11-20

None of those conditions is improper. Prepaying for six or twelve months is a legitimate trade, and so is a yearly membership. The point is that each seller prints the condition next to the number. RonanRx’s video, as FDA quotes it, offered a monthly figure and a claim about where the drug was made, with no condition attached.

What would $78 a month cost over a year, against real alternatives?

If $78 were a price you could keep every month, a year would cost $936. That is cheap but not impossible: it is $9 a month, or $108 a year, below the lowest standing month-to-month price on our sheet, Mondae’s $87. It is also $108 a year more than the cheapest prepaid years on our sheet, which already reach $828.

Twelve months of compounded semaglutide at prices read November 20, 2026 (USD; NexLife’s prices as of November 6, 2026)
RouteHow you payArithmetic12 months
Mondae, Yucca Health or Galaprepaid 6- or 12-month plans2 × $414, or $828, or 12 × $69$828
Collectivemonthly plus a yearly membership12 × $59 + $199$907
An advertised $78 that never changesmonthly (hypothetical)12 × $78$936
Mondaemonth to month12 × $87$1,044
Yucca Healthmonth to month12 × $89$1,068
NexLife12-month plan, paid up front per its FAQ12 × $95$1,140
Edenmonth to month12 × $99$1,188
NexLifemonth to month12 × $109$1,308

The arithmetic says the same thing as the chart. A $78 figure is within the range honest sellers reach, so its size tells you little. Our 12-month cost page carries the full set.

What do FDA’s 2026 letters to telehealth sellers have in common?

Labels. FDA’s warning-letter index lists 56 telehealth letters dated in 2026 for false or misleading claims, none closed out as of November 20, 2026. In each of the four that we have read in full, FDA objected to product pictures that showed the seller’s own name on the vial as if it compounded the drug. Two of the four went to programs on our homepage.

FDA warning letters to GLP-1 telehealth sellers that we have read on fda.gov (read November 20, 2026)
LetterRecipientDatedSeller’s name shown as compounderOther claims FDA cited
721455MEDViFeb 20, 2026Yes“Same active ingredient as” Wegovy, Ozempic, Mounjaro and Zepbound
730096NexLifeJun 8, 2026YesWebsite claims about compounded semaglutide and tirzepatide false or misleading
728279EdenJun 8, 2026YesSuppliers described as “FDA-licensed 503(a) outsourcing facilities”
737905RonanRxOct 30, 2026Yes“FDA-Approved Compounded Medications”, “American made”, “farm-to-table”, the $78 video

NexLife is our editor’s pick and Eden is on our homepage, so we say this plainly: both letters are deducted in the regulatory part of our v4.1 scores, and both provider files describe them. NexLife says it responded and, as of November 12, that FDA had not published a close-out letter.

Why is “American made” a claim you can check?

Because the active ingredient in compounded semaglutide and tirzepatide is imported. FDA told RonanRx that its records list no U.S.-registered maker of either ingredient for compounding. Its revised Import Alert 66-80, published October 9, 2026, lets inspectors hold foreign GLP-1 ingredients at the border unless the firm is on a “green list”, and FDA says 21% of the 48 ingredient sites it evaluated were noncompliant. A U.S. pharmacy can compound the vial; that does not make the drug inside it American made.

What this means for you

Judge a low compounded GLP-1 price by what surrounds it. Before you pay, check five things:

  1. The word “approved”. Compounded semaglutide and tirzepatide are never FDA-approved. A seller who says otherwise has told you something more important than its price.
  2. The compounding pharmacy. Ask which pharmacy compounds your prescription and look for its name on the label. Our pharmacy disclosure index shows which programs name theirs.
  3. The condition. Find out whether the number is a sale, a prepaid term, a membership or a “starting at” figure. If the page does not say, ask in writing.
  4. The standing floor. On November 20, 2026 the lowest semaglutide price on our sheet printed as month to month, with no sale, prepayment or membership, was $87 at Mondae, then $89 at Yucca Health and $99 at Eden (NextMeds’ $49 “starting at” figure prints no plan term). Tirzepatide started at $126 on our sheet.
  5. The FDA record. Search the program and its pharmacy in FDA’s warning-letter database and recent recalls. Our lookup guide lists what we have found.

Our legitimacy checklist walks through each step.

What we do not know

We do not track RonanRx and have not read its current pages, so we cannot say whether it still advertises $78 or how it answered FDA. The letter is FDA’s account of what it found in September 2026. This report sets that account against the prices we do track; it does not rate RonanRx.

Compare every semaglutide price → Run the legitimacy checklist

Frequently asked questions

Is a $78-a-month compounded semaglutide price a scam?
Not by itself. On November 20, 2026, 12 of the 49 semaglutide programs on our sheet printed a lowest figure of $78 or less, each with a condition such as a sale, a prepaid term or a membership. A low price is a reason to ask what it depends on and who compounds the drug, not proof of fraud.
Did FDA say RonanRx’s $78 price was illegal?
No. FDA quoted the “seventy-eight dollars a month” video as part of the misleading marketing, alongside “FDA-Approved Compounded Medications”, “American made” and labels showing RonanRx as the compounder. The letter, dated October 30, 2026, objects to the claims; it does not set or forbid a price.
What is the lowest compounded semaglutide price I can keep month to month?
On November 20, 2026 the lowest standing month-to-month prices on our sheet with no sale, prepayment or membership were Mondae at $87, Yucca Health at $89 and Eden at $99; NextMeds prints $49 “starting at” with no plan term. NexLife charges $109 month to month or $95 a month on its 12-month plan, as of November 6, 2026.
Can compounded semaglutide be FDA-approved?
No. Compounded semaglutide and tirzepatide are prepared by a pharmacy for an individual prescription and are not FDA-approved, are not generics and are not the same products as Ozempic, Wegovy, Mounjaro or Zepbound. FDA says disclaimers do not cure a misleading “approved” label.
What should my compounded GLP-1 vial label show?
The pharmacy that compounded it, along with the drug, strength and directions. In 2026 FDA warned four telehealth sellers whose product pictures showed the seller’s own name as if it compounded the drug. If your label names a company that is not a pharmacy, ask who made the vial.
Has FDA sent warning letters to programs this site lists?
Yes. FDA’s warning-letter index, read November 20, 2026, lists telehealth letters to 16 programs in our dataset, none closed out: NexLife (730096) and Eden (728279), June 8, 2026; OrderlyMeds, June 8, 2026; MEDVi (721455), Ivim, Zappy, Strut, SkinnyRx, Levity and Fifty 410, February 20, 2026; and Hims & Hers, Zealthy, Sprout Health, Direct Meds, Remedy Meds and Curex, September 9, 2025. Each provider file gives the letter number and subject. Only NexLife and Eden are among the eight programs we score, and both letters are deducted.

Sources

  1. U.S. FDA, warning letter 737905 to RonanRx, dated October 30, 2026, posted November 3, 2026, read November 20, 2026.
  2. U.S. FDA, warning letter 730096 to Nexlife Inc., dated June 8, 2026, read November 20, 2026.
  3. U.S. FDA, warning letter 728279 to Eden Health International, dated June 8, 2026, read November 20, 2026.
  4. U.S. FDA, warning letter 721455 to MEDVi, dated February 20, 2026, read November 20, 2026.
  5. U.S. FDA, Import Alert 66-80 (GLP-1 active ingredients), published October 9, 2026, read November 20, 2026.
  6. U.S. FDA, Concerns with unapproved GLP-1 drugs used for weight loss, content current October 1, 2026, read November 20, 2026.
  7. WellMedr, get-started page, read November 20, 2026.
  8. NextMeds, homepage, read November 20, 2026.
  9. Fridays, pricing, read November 20, 2026.
  10. Mondae, compounded semaglutide, read November 20, 2026.
  11. Yucca Health, GLP-1 plans and pricing, read November 20, 2026.
  12. Gala GLP-1, compounded semaglutide, read November 20, 2026.
  13. SnagRx, homepage, read November 20, 2026.
  14. PreventiveMD, semaglutide protocol, read November 20, 2026.
  15. Collective, weight-loss program, read November 20, 2026.
  16. Sunlight, homepage, read November 20, 2026.
  17. Eden, GLP-1 treatments, read November 20, 2026.
  18. NexLife, semaglutide plans, prices as of November 6, 2026, re-read November 20, 2026.

Researched By

Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By

Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.